Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY2416964 · 1 trial · 1 indication
MTD:defined as the dose level that can be given such that the estimated Dose limiting toxicity (DLT) probability is closest to approximately 25%.
Integration of all available safety, PK and PD data
| Arm | Type | Description |
|---|---|---|
| Dose escalation of BAY2416964 | EXPERIMENTAL | Approximately 8 dose levels of BAY2416964 are planned |
| Dose expansion of BAY2416964 in tumor type specific | EXPERIMENTAL | Patients with NSCLC, HNSCC |
| Name | Type | Description |
|---|---|---|
| BAY2416964 | DRUG | Oral application of study drug daily in a predefined dose escalation scheme. |
Inclusion Criteria: * Participants must be ≥18 years of age inclusive, at the time of signing the informed consent. * Participants with following histologically or cytologically confirmed advanced solid tumors that have progressed after treatment with all available therapies for metastatic disease ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BAY2416964 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, and a first-in-human trial has been completed to evaluate its safety and tolerability in patients with advanced cancer.
BAY2416964 is an aryl hydrocarbon receptor (AhR) inhibitor. It works by blocking the activity of the aryl hydrocarbon receptor, which is involved in tumor progression and immune suppression. This mechanism is being explored as a potential therapeutic approach for advanced solid tumors.
BAY2416964 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY2416964 is in Phase 1 clinical development. A first-in-human dose-finding study has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation for advanced solid tumors.
BAY2416964 has been studied in one completed Phase 1 clinical trial, identified as NCT04069026. This trial was a first-in-human dose-finding study that enrolled 78 patients with advanced solid tumors across the United States, Canada, Germany, Spain, and the United Kingdom.
BAY2416964 is an aryl hydrocarbon receptor (AhR) inhibitor, and it is sometimes referred to as an AhRi in clinical trial documentation. It is a small molecule designed to inhibit the aryl hydrocarbon receptor, and it is being investigated for the treatment of advanced solid tumors.